Electrodiagnostic Medicine Patient Protection and Fraud Elimination Act of 2023

Hozzl · 2024-12-21T09:05:23Z

Explore the details of House Bill 2639 Electrodiagnostic Medicine Patient Protection and Fraud Elimination Act of 2023 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

12/21/2024, 9:05 AM

Summary of Bill HR 2639

Bill 118 HR 2639, also known as the Electrodiagnostic Medicine Patient Protection and Fraud Elimination Act of 2023, aims to address issues related to fraud and abuse in the field of electrodiagnostic medicine. This bill seeks to protect patients by establishing guidelines and regulations for healthcare providers who perform electrodiagnostic tests.

The bill outlines specific requirements for healthcare providers who perform electrodiagnostic tests, such as nerve conduction studies and electromyography. These requirements include obtaining informed consent from patients, maintaining accurate records of test results, and ensuring that tests are performed by qualified professionals.

Additionally, the bill includes provisions to prevent fraud and abuse in the billing and reimbursement of electrodiagnostic tests. Healthcare providers are required to submit accurate and timely claims for reimbursement, and penalties are established for providers found to be engaging in fraudulent billing practices. Overall, the Electrodiagnostic Medicine Patient Protection and Fraud Elimination Act of 2023 aims to improve patient safety and ensure the integrity of electrodiagnostic testing practices. By establishing guidelines and regulations for healthcare providers, this bill seeks to protect patients from potential harm and prevent fraudulent practices in the field of electrodiagnostic medicine.

Congressional Summary of HR 2639

Electrodiagnostic Medicine Patient Protection and Fraud Elimination Act of 2023

This bill requires, as a condition for Medicare payment, specified electrodiagnostic services to be furnished by qualified facilities that comply with accreditation, training, and other quality control requirements, as established under the bill.

Specifically, the bill requires nerve conduction studies and needle electromyography tests to be furnished by facilities that are accredited by an organization that is approved by the Centers for Medicare & Medicaid Services (CMS). The accrediting organization must certify that the facility meets certain standards, including having a quality control program and requiring those who administer needle electromyography tests to have at least three months of specialized training.

The bill also establishes an advisory committee to support the CMS in developing appropriate facility standards.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 2639

Bill HR 2639 is currently in the status of Bill Introduced since April 17, 2023. Bill HR 2639 was introduced during Congress 118 and was introduced to the House on April 17, 2023. Bill HR 2639's most recent activity was Referred to the Subcommittee on Health. as of December 17, 2024

Bipartisan Support of Bill HR 2639

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 2639

Primary Policy Focus

Health

Alternate Title(s) of Bill HR 2639

Electrodiagnostic Medicine Patient Protection and Fraud Elimination Act of 2023

To amend title XVIII of the Social Security Act to provide for additional requirements with respect to electrodiagnostic services under the Medicare program.